Skip to main content
. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191

Figure 1. Plasma LCN2 levels and albumin quotient in patients with MS and controls.

Figure 1

Plasma levels of lipocalin-2 (LCN2) and albumin quotient in (A, B) symptomatic controls (SC), inflammatory neurologic disease controls (INDC), and patients with multiple sclerosis (MS); in (C, D) patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS); and in (E, F) patients in RRMS remission and RRMS relapse. *p < 0.05, **p < 0.01, and ****p < 0.0001.